Genmab — November 2019
-
Plesner/Abildgaard får afslag på off-label venetoclax i HR MM https://haematologisktidsskrift.dk/sygdomme/myeloma/648-myelomatoseeksperter-far-afslag-pa-off-label-behandling-med-god-effekt.html
-
Jeps...Og pladsen bliver vist hele tiden større i dag.
-
Der ligger vist ikke et rebound i kortene i dag.
-
?
-
Den slags er noget nyt.
-
HALO skærer virksomheden til ved at fyre over halvdelen af medarbejderne samt fokusere på det stof der bruges i dara sc. Mener det kan blive en rigtig god langsigtet investering med tanke på at dara sc kaster 5% royalty af sig. Herudover mange andre tilsvarende aftaler. Sorry for at benytte Genmab chatten - vi kunne tage den i biotech chatten.
-
Tragisk..David Eatwell mistede sin hustru i sommers. Derfor logisk, at han trækker sig for af hensyn til børnene.https://borsen.dk/nyheder/virksomheder/artikel/1/390639/genmabs_jan_van_de_winkel_familiedrama_bag_finansdirektoers_exit.html
-
NextCure stiger beskedne 183% efter at have været oppe med 221% pga af data fra et fase 1 studie: Results from the just-published abstract showed one complete response (41 weeks to date), one partial response (14 weeks to date) and a disease control rate (DCR) of 71% (n=5/7) in patients with non-small cell lung cancer (NSCLC) who received NC318 alone. Response data from 11 additional patients will be presented on Saturday. Bare vent til kl 15 i morgen når cd3xcd20 kommer på gaden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind